ME/CFS affects 67 million people worldwide, yet the disease has no diagnostic markers, no approved treatments, and fewer than 10% of patients recover. PRIME will build the first permanent research infrastructure for the condition, connecting patients, researchers, and industry to reverse decades of scientific neglect. The problem is stark: ME/CFS costs the UK £3.3 billion annually, 63% of patients cannot work, and one in four are house- or bed-bound. But the science has been marginalised—few established research groups, no dedicated journals, and findings that are rarely replicated. PRIME directly addresses this by injecting ME/CFS questions into mainstream biomedical science. Over four years, the project will forge around 15 new collaborations with industry and other scientists, catalyse at least £1 million in follow-on funding for biomarker and mechanistic studies, and establish international consortia spanning four countries. It will also create the world’s largest ME/CFS patient and public involvement pool, with 100 volunteer participants, ensuring people with the condition govern the research. If successful, PRIME will transform ME/CFS from a neglected field into one with replicable findings, diagnostic pathways, and a permanent infrastructure that attracts sustained investment—ultimately enabling effective diagnosis and treatment.
View original technical description
Myalgic Encephalomyelitis (also known as Chronic Fatigue Syndrome; ME/CFS) affects approximately 67 million people worldwide, including >250,000 in the UK1. One in four people with ME/CFS are house- or bed-bound, often needing 24-hour care2,3. 63% of UK ME/CFS patients are unable to work2. ME/CFS costs £3.3 billion annually in the UK4. Recovery rates are low (<10%)5,6. In rare cases, ME/CFS is fatal7. Despite these statistics, people with ME/CFS - according to Mohammad Yasin, MP -"are often stigmatised and marginalised, as their conditions are not fully recognised by the Government or the medical profession” (Appropriate ME Treatment Debate, 2019). The UK Government’s Interim Delivery Plan for ME emphasises low critical mass of research8 despite the MRC’s long-standing Highlight Notice9. Currently ME/CFS research sits at the margins of science and medicine, and its findings are rarely replicated10,11 leading to myriad hypotheses that have yet to make a breakthrough for patients, biotech companies or clinical researchers. Internationally, ME/CFS has few established research groups or conferences, and no dedicated journals. ME/CFS has no available diagnostic markers or treatment avenues. For advancement, ME/CFS cannot rely on serendipitous interactions across institutions and disciplines because it currently falls far short of attaining critical mass of researchers and studies. Our project will inject ME/CFS questions and evidence into mainstream contemporary science, catalysing other biomedical expertise and disciplines to investigate ME/CFS. PRIME’s driving principles are to: (1) Accelerate ME/CFS biomedical research by catalysing novel interdisciplinary collaborations; (2) Enhance the quality and cross-applicability of ME/CFS biomedical research given the co-morbidities with other diseases; and, (3) Ensure that people with ME/CFS are at the heart of the governance, design and delivery of ME/CFS science. PRIME will take advantage of previous MRC/NIHR investment in DecodeME, its findings, consented-for-recall cohort and researcher/PPI co-production success. Its second focus on biomarkers draws on recent UK Biobank discoveries. Within 4-years PRIME will: Forge =15 novel collaborations with industry and/or other scientists who take advantage of DecodeME as a bioresource and catalyse =£1,000,000 in funding for replicable biomarker investigations, mechanistic experiments, and/or studies such as a ME/CFS Whole Genome Sequencing (WGS) study with a UK-based Life Sciences champion. Help establish international ME/CFS and ‘Omics Consortia involving =6 groups from =4 countries. These will facilitate meta-analysis of ME/CFS data across diverse genetic ancestries to ensure inclusion and broad relevancy of results and lead to improved and accelerated research, highlighting best practice thereby saving both time and funds. Establish the world’s largest ME/CFS PPI expert pool with =100 PPI volunteer participants, helping to raise the quantity and quality of ME/CFS biomedical and clinical research. The PPI pool will provide a long-term resource for the research communities of ME/CFS’s comorbid conditions. In summary, PRIME will build a solid foundation for a permanent, enabling infrastructure for ME/CFS biomedical research that will reverse decades of under-investment and unreplicated research findings, ultimately leading to effective diagnosis and treatment. References Hanson & Germain (2020) doi.org/10.3390/metabo10050216 Pendergrast et al. (2016) doi.org/10.1177/1742395316644770 Montoya et al. (2021) doi.org/10.3390/healthcare9101331 Hunter et al. (2017) https://2020health.org/wp-content/uploads/2020/11/Counting-the-Cost-CFS-ME.pdf Joyce et al. (1997) doi.org/10.1093/qjmed/90.3.223 Cairns & Hotopf (2005) doi.org/10.1093/occmed/kqi013 McManimen et al. (2016) doi.org/10.1080/21641846.2016.1236588. My full reality: the interim delivery plan on ME/CFS, https://www.gov.uk/government/consultations/improving-the-experiences-of-people-with-mecfs-interim-delivery-plan/my-full-reality-the-interim-delivery-plan-on-mecfs MRC Highlight Notice for ME/CFS https://www.ukri.org/opportunity/researching-me-cfs-highlight-notice/ Dibble et al. (2020) doi.org/10.1093/hmg/ddaa169 Maksoud et al. (2023) doi.org/10.1186/s12916-023-02893-9
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know